Nektar Therapeutics (NKTR) News Today

Nektar Therapeutics (NASDAQ: NKTR) is under pressure after a fresh round of analyst updates focused on its earnings outlook. The stock is lower today as investors digest mixed earnings revisions and a lowered price target from Wedbush.

• Positive Sentiment: HC Wainwright kept a Buy rating on Nektar Therapeutics and maintained a high $185 price target, signaling continued long-term upside potential for the biopharmaceutical company.
• Positive Sentiment: The firm raised several future earnings estimates, including FY2026, FY2027, FY2028, FY2029, and FY2030, suggesting improving expectations over the longer term.
• Neutral Sentiment: HC Wainwright also updated near-term quarterly forecasts for Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, and Q4 2027, reflecting a broader refresh of its model rather than a company event.
• Negative Sentiment: Despite the optimistic rating from HC Wainwright, the company continues to be expected to post substantial losses over the next several years, which can weigh on sentiment for a still-unprofitable biotech name.
• Negative Sentiment: Wedbush reportedly lowered its price target to $80, adding a more cautious view that may be contributing to the stock’s weakness.

Overall, Nektar Therapeutics (NASDAQ: NKTR) appears to be moving lower because investors are balancing encouraging analyst support against ongoing loss forecasts and a reduced valuation target from another firm.